Effectiveness of a sodium glucose cotransporter 2 inhibitor as a part of early combined therapy in diabetes mellitus type 2. Clinical case

• Blagova V.N.

Abstract

Nowadays over 415 mln individuals, or 6% adults, suffer from diabetes mellitus type 2 worldwide. Timely diagnosis and treatment of diabetes mellitus type 2 can prevent from and delay development of complications. It is crucial to focus on control of carbohydrate and lipid metabolism, nephroprotection, and blood pressure indicator as well as cardiovascular complications. Development of diabetes mellitus type 2 is a multicomponent mechanism. Considering that monotherapy fails to control glycemia in the long term, early combined therapy is physiologically based and advantageous. A new class of drugs with insulin-independent mechanism of action, sodium glucose cotransporter 2 inhibitors like dapagliflozin, is promising.

Objective - to evaluate effectiveness of a sodium glucose cotransporter 2 inhibitor (dapagliflozin, 10 mg) as adjuvant therapy in metformin treatment as compared to metformin monotherapy as a part of diabetes mellitus type 2 management.

Material and methods. An inpatient with established diagnosis of diabetes mellitus type 2 (DM2 duration of <3 months). After informed consent had been obtained, laboratory and imaging assessments were performed. They included continuous glucose monitoring, threefold daily self-control of glycemic indicators with a portable glucose meter during 14 days.

Results. A positive change, decreased glycemia variability, has been observed in early combined glucose-lowering therapy.

Conclusion. Use of dapagliflozin as a part of DM2 early combined therapy improves glycemic control.

Keywords:diabetes mellitus type 2, glycemia variability, early combined therapy, dapagliflozin

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)